Kuwashima Y, Shisa H, Uehara T, Kurosumi M, Kobayashi Y, Tanuma J, Shiromizu K, Matsuzawa M, Kishi K
Department of Pathology, Saitama Cancer Center, Japan.
Anticancer Res. 1995 Nov-Dec;15(6B):2847-50.
Expression of ras p21 oncoproteins in human ovarian carcinomas was examined immunohistochemically by using a monoclonal antibody(clone RAS 10) with respect to the degree of their histological differentiation. To achieve this, the intensity of staining for the protein was compared between undifferentiated and well differentiated carcinomas, i.e. extreme subtypes of common epithelial carcinomas. The former was composed of 8 "solid" carcinomas and the latter, 11 serous, 8 mucinous, 4 endometrioid and 4 clear cell carcinomas. All the cases examined, including both undifferentiated and well-differentiated carcinomas, showed a positive reaction to this antibody. Staining intensity and the number of positive cells somewhat varied among the cases. Additionally, 2 cases of ovarian epithelial tumors of low malignant potential (I,MP) were stained with this antibody. Both the cases were positive, but the number of positive cells seemed to be rather less than that found in the carcinoma groups. Thus, no differences in ras p21 expression were observed between the cases examined in spite of the differences in the degree of differentiation of the epithelial ovarian carcinomas. However, the possibility remained that the number of positive cells could be an indicator of malignant potential, enabling us to distinguish LMPs from carcinomas.
使用单克隆抗体（克隆RAS 10）通过免疫组织化学方法检测人卵巢癌中ras p21癌蛋白的表达情况，并观察其组织学分化程度。为此，比较了未分化癌和高分化癌（即常见上皮性癌的极端亚型）中该蛋白的染色强度。前者由8例“实性”癌组成，后者包括11例浆液性癌、8例黏液性癌、4例子宫内膜样癌和4例透明细胞癌。所有检测病例，包括未分化癌和高分化癌，对该抗体均呈阳性反应。不同病例的染色强度和阳性细胞数量略有差异。此外，用该抗体对2例低恶性潜能（LMP）卵巢上皮性肿瘤进行染色。这2例均为阳性，但阳性细胞数量似乎比癌组少。因此，尽管卵巢上皮性癌的分化程度不同，但在所检测病例中未观察到ras p21表达的差异。然而，阳性细胞数量仍有可能作为恶性潜能的指标，使我们能够将LMP与癌区分开来。
